Scinai Immunotherapeutics (SCNI) Operating Leases (2019 - 2026)

Scinai Immunotherapeutics (SCNI) has 8 years of Operating Leases data on file, last reported at $2.9 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Leases changed N/A year-over-year to $2.9 million; the trailing twelve-month figure through Mar 2026 stood at $2.9 million (changed N/A YoY), and the FY2025 full-year result was $1.6 million, up 17.26% from the prior year.
• Operating Leases improved to $2.9 million in Q1 2026, from $1.6 million in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $2.9 million in Q1 2026 to a low of $343000.0 in Q4 2023.
• A 5-year average of $1.1 million and a median of $875000.0 in 2023 frame the typical range for Operating Leases.
• Across the five-year window, Operating Leases slumped 75.73% in 2022 and surged 308.75% in 2024, its largest moves.
• Tracing SCNI's Operating Leases over 5 years: stood at $351000.0 in 2022, then retreated by 2.28% to $343000.0 in 2023, then soared by 308.75% to $1.4 million in 2024, then increased by 17.26% to $1.6 million in 2025, then surged by 73.66% to $2.9 million in 2026.
• Business Quant data shows SCNI's Operating Leases at $2.9 million in Q1 2026, $1.6 million in Q4 2025, and $1.6 million in Q2 2025.